# A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin

> **NCT06112808** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Biocad** · enrollment: 300 (estimated)

## Conditions studied

- Advanced Melanoma

## Interventions

- **DRUG:** BCD-263
- **DRUG:** Opdivo

## Key facts

- **NCT ID:** NCT06112808
- **Lead sponsor:** Biocad
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-05-29
- **Primary completion:** 2024-01-31
- **Final completion:** 2027-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06112808

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06112808, "A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06112808. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*